Scientific Image and Illustration Software| BioRender

Huntington’s Disease - Symptoms, Causes, Treatment| NORD

Rojas NG, Cesarini ME, Peker G, Da Prat GA, Etcheverry JL, Gatto EM (2022) Review of Huntington’s Disease: from basics to advances in diagnosis and treatment. J Neurol Res 12

Ghosh R, Tabrizi SJ (2018) Clinical features of Huntington’s disease. Adv Exp Med Biol 1049:1–28

Article  CAS  PubMed  Google Scholar 

Walker FO (2007) Huntington’s disease. Lancet 369:218–228

Article  CAS  PubMed  Google Scholar 

Huntington Study Group COHORT Investigators &, Dorsey ER (2012) Characterization of a large group of individuals with huntington disease and their relatives enrolled in the COHORT study. PLoS ONE 7:e29522

Article  Google Scholar 

Bates GP, Dorsey R, Gusella JF, Hayden MR, Kay C, Leavitt BR, Nance M, Ross CA, Scahill RI, Wetzel R, Wild EJ, Tabrizi SJ (2015) Huntington disease. Nat Rev Dis Primers 1:15005

Article  PubMed  Google Scholar 

Wyant KJ, Ridder AJ, Dayalu P (2017) Huntington’s Disease-Update on treatments. Curr Neurol Neurosci Rep 17:33

Article  PubMed  Google Scholar 

Dumas EM, van den Bogaard SJA, Middelkoop HAM, Roos RAC (2013) A review of cognition in Huntington’s disease. Front Biosci (Schol Ed) 5:1–18

Article  PubMed  Google Scholar 

Kumar A, Kumar V, Singh K, Kumar S, Kim Y-S, Lee Y-M, Kim J-J (2020) Therapeutic advances for Huntington’s disease. Brain Sci 10

Wellington CL, Leavitt BR, Hayden MR (2000) Huntington disease: new insights on the role of huntingtin cleavage. J Neural Transm 58(Suppl):1–17

Sánchez-Pernaute R, García-Segura JM, del Barrio Alba A, Viaño J, de Yébenes JG (1999) Clinical correlation of striatal 1H MRS changes in Huntington’s disease. Neurology 53:806–812

Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C (2009) Therapeutic interventions for disease progression in Huntington’s disease. Cochrane Database Syst Rev 2009, CD006455

Safety and tolerability of WVE-120102 in patients with Huntington’s Disease (2017). ClinicalTrials.gov

Safety and tolerability of WVE-120101 in patients with Huntington’s Disease (2017). ClinicalTrials.gov

GENERATION HD2 A study to evaluate the safety, biomarkers, and efficacy of Tominersen compared with placebo in participants with Prodromal and Early Manifest Huntington’s Disease (2023). ClinicalTrials.gov

A study to evaluate the efficacy and safety of Intrathecally Administered RO7234292 (RG6042) in participants with Manifest Huntington’s Disease (2019). ClinicalTrials.gov

Kordasiewicz HB, Stanek LM, Wancewicz EV, Mazur C, McAlonis MM, Pytel KA, Artates JW, Weiss A, Cheng SH, Shihabuddin LS, Hung G, Bennett CF, Cleveland DW (2012) Sustained therapeutic reversal of Huntington’s disease by transient repression of huntingtin synthesis. Neuron 74:1031–1044

Article  CAS  PubMed  PubMed Central  Google Scholar 

McBride JL, Pitzer MR, Boudreau RL, Dufour B, Hobbs T, Ojeda SR, Davidson BL (2011) Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington’s disease. Mol Ther 19:2152–2162

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marxreiter F, Stemick J, Kohl Z (2020) Huntingtin lowering strategies. Int J Mol Sci 21

Culver BP, Savas JN, Park SK, Choi JH, Zheng S, Zeitlin SO, Yates JR, Tanese N (2012) Proteomic analysis of wild-type and mutant huntingtin-associated proteins in mouse brains identifies unique interactions and involvement in protein synthesis. J Biol Chem 287:21599–21614

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dragatsis I, Levine MS, Zeitlin S (2000) Inactivation of hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat Genet 26:300–306

Article  CAS  PubMed  Google Scholar 

Wang G, Liu X, Gaertig MA, Li S, Li X-J (2016) Ablation of huntingtin in adult neurons is nondeleterious but its depletion in young mice causes acute pancreatitis. Proc Natl Acad Sci USA 113:3359–3364

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu J-P, Zeitlin SO (2017) Is huntingtin dispensable in the adult brain? J Huntingtons Dis 6:1–17

Article  PubMed  PubMed Central  Google Scholar 

Shannon KM (2020) Recent advances in the treatment of Huntington’s disease: targeting DNA and RNA. CNS Drugs 34:219–228

Article  CAS  PubMed  Google Scholar 

Zuccato C, Valenza M, Cattaneo E (2010) Molecular mechanisms and potential therapeutical targets in Huntington’s disease. Physiol Rev 90:905–981

Article  CAS  PubMed  Google Scholar 

Sweeney MD, Zhao Z, Montagne A, Nelson AR, Zlokovic BV (2019) Blood-brain barrier: from physiology to Disease and back. Physiol Rev 99:21–78

Article  CAS  PubMed  Google Scholar 

Pardridge WM (2005) The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2:3–14

Article  PubMed  PubMed Central  Google Scholar 

Li B, Tang Q, Cheng D, Qin C, Xie FY, Wei Q, Xu J, Liu Y, Zheng B, Woodle MC, Zhong N, Lu PY (2005) Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat Med 11:944–951

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thakker DR, Natt F, Hüsken D, Maier R, Müller M, van der Putten H, Hoyer D, Cryan JF (2004) Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference. Proc Natl Acad Sci USA 101:17270–17275

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mendonça MCP, Cronin MF, Cryan JF, O’Driscoll CM (2021) Modified cyclodextrin-based nanoparticles mediated delivery of siRNA for huntingtin gene silencing across an in vitro BBB model. Eur J Pharm Biopharm 169:309–318

Article  PubMed  Google Scholar 

Burgess A, Huang Y, Querbes W, Sah DW, Hynynen K (2012) Focused ultrasound for targeted delivery of siRNA and efficient knockdown of htt expression. J Control Release 163:125–129

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hynynen K, McDannold N, Vykhodtseva N, Jolesz FA (2001) Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. Radiology 220:640–646

Article  CAS  PubMed  Google Scholar 

Harper SQ, Staber PD, He X, Eliason SL, Martins IH, Mao Q, Yang L, Kotin RM, Paulson HL, Davidson BL (2005) RNA interference improves motor and neuropathological abnormalities in a Huntington’s disease mouse model. Proc Natl Acad Sci USA 102:5820–5825

Article  CAS  PubMed  PubMed Central  Google Scholar 

Andreassen OA, Dedeoglu A, Ferrante RJ, Jenkins BG, Ferrante KL, Thomas M, Friedlich A, Browne SE, Schilling G, Borchelt DR, Hersch SM, Ross CA, Beal MF (2001) Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington’s disease. Neurobiol Dis 8:479–491

Article  CAS  PubMed  Google Scholar 

Segarra M, Aburto MR, Acker-Palmer A (2021) Blood-brain Barrier dynamics to maintain Brain Homeostasis. Trends Neurosci 44:393–405

Article  CAS  PubMed  Google Scholar 

Bhattacharya A, Kaushik DK, Lozinski BM, Yong VW (2020) Beyond barrier functions: roles of pericytes in homeostasis and regulation of neuroinflammation. J Neurosci Res 98:2390–2405

Article  CAS  PubMed  Google Scholar 

Fong CW (2015) Permeability of the blood-brain barrier: Molecular Mechanism of Transport of Drugs and physiologically important compounds. J Membr Biol 248:651–669

Article  CAS  PubMed  Google Scholar 

Olesen SP, Crone C (1983) Electrical resistance of muscle capillary endothelium. Biophys J 42:31–41

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wasielewska JM, White AR (2022) Focused Ultrasound-mediated drug delivery in humans - a path towards translation in neurodegenerative diseases. Pharm Res 39:427–439

Article  CAS  PubMed  PubMed Central  Google Scholar